Novartis Lp(a)-lowering drug pelacarsen cuts biomarker but not heart attacks in trial

A large cardiovascular outcomes trial of pelacarsen, which substantially reduced circulating Lp(a), showed no significant reduction in myocardial infarction or stroke, raising questions about Lp(a) as a therapeutic target.

Published · AI-drafted summary based on 1 public source
Illustration for generic story
Illustrative image — not from the source article.
Share

Item [7] from Stat News reports on a clinical trial failure presented at the American Heart Association (AHA) 2026 conference: Novartis's pelacarsen, an RNA-targeted therapy designed to lower lipoprotein(a) — Lp(a) — reduced circulating Lp(a) levels as expected but did not translate this into a statistically significant reduction in hard cardiovascular endpoints, including myocardial infarction and stroke.

Lp(a) is an inherited, largely genetically determined lipoprotein particle whose elevated levels are associated with increased cardiovascular risk in population and genetic studies. The disconnect between biomarker reduction and clinical outcome mirrors earlier frustrations in the cardiovascular field, such as HDL-raising agents that also failed to show event reduction. Researchers at the AHA conference are reported to be re-examining whether Lp(a) itself is a causal risk factor or a marker correlated with other causal mechanisms.

The result has particular relevance for genetic researchers given that Lp(a) levels are largely controlled by variation at the LPA locus, and Genetic Current recently covered a preprint using naturally occurring LPA loss-of-function variants in a Pakistani cohort to explore drug-target validation (27 October 2026). That preprint used genetic evidence to anticipate cardiovascular benefit from Lp(a) lowering; the pelacarsen trial result now provides an important empirical counterpoint. Item [7] is behind a Stat News paywall; editorial notes are based on the available lede and feed-tag metadata.

Sources

Read the original reporting — these are the public sources this summary draws from.

  1. Primary source Stat News · 2026-11-07
    Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy

Tags

lpa lipoprotein-a pelacarsen cardiovascular-disease clinical-trial-news drug-target-validation aha-conference genetics
Share

About Genetic Current

Educational summaries of public genetics news

Genetic Current is the news section of Evagene, an academic, research, and educational pedigree-modelling platform. Stories are AI-drafted summaries of items from trusted public sources, written for researchers, clinicians, educators, students, genealogists, and patients with an interest in genetics. Summaries are for educational and research purposes only and are not medical advice.

Join the Evagene Alpha Waiting List